11月12日，Recursion Pharmaceuticals, Inc.盘前下跌5.01%，报3.4102美元/股，成交额105.92万美元。
消息面上，公司此前披露REC-4881二期更新数据，显示家族性腺瘤性息肉病患者息肉负担明显下降，且安全性较为清洁，并支持推进注册性试验；但在前一交易日相关利好已推动股价盘前上涨后，市场当前更继续评估该项目后续注册推进与估值修复空间。
此外，公司近期还披露三季度营收1855万美元，高于预期的1478.3万美元，EPS为每股亏损0.22美元；同时任命资深医药行业高管Fred Hassan出任董事长，持续强化外界对其AI制药平台商业化路径的关注。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.